首页> 美国卫生研究院文献>other >Preclinical testing of anti-human CD28 Fab’ antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD)
【2h】

Preclinical testing of anti-human CD28 Fab’ antibody in a novel nonhuman primate (NHP) small animal rodent model of xenogenic graft-versus-host disease (GVHD)

机译:在异种移植物抗宿主病(GVHD)的新型非人灵长类动物(NHP)小动物啮齿动物模型中抗人CD28 Fab抗体的临床前测试

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGraft-versus-host disease (GVHD) is a severe complication of hematopoietic stem cell transplantation. Current therapies to prevent alloreactive T cell activation largely cause generalized immunosuppression and may result in adverse drug, anti-leukemia and anti-pathogen responses. Recently, several immunomodulatory therapeutics have been developed that show efficacy in maintaining anti-leukemia responses while inhibiting GVHD in murine models. To analyze efficacy and better understand immunological tolerance, escape mechanisms, and side-effects of clinical reagents, testing of species-cross-reactive human agents in large animal GVHD models is critical.
机译:背景移植物抗宿主病(GVHD)是造血干细胞移植的严重并发症。当前防止同种异体性T细胞活化的疗法在很大程度上引起普遍的免疫抑制,并可能导致不良的药物,抗白血病和抗病原体反应。近来,已经开发了几种免疫调节疗法,其显示出在维持抗白血病反应的功效同时在鼠模型中抑制GVHD的功效。为了分析功效并更好地理解临床试剂的免疫耐受性,逃逸机制和副作用,在大型动物GVHD模型中测试物种交叉反应性人类试剂至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号